Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 3Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thymoma 1Neoplastic Cells, Circulating 1Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Lobular 1

Interventions

pembrolizumab 16Radiotherapy 15Drug Therapy 14Paclitaxel 13Cisplatin 12Carboplatin 10Immunotherapy 9Esophagectomy 9Radiation 8Fluorouracil 8Surgical Procedures, Operative 7Capecitabine 7Blood Specimen Collection 7Oxaliplatin 6Nivolumab 6Immune Checkpoint Inhibitors 6Chemoradiotherapy 6nimotuzumab 5Trastuzumab 5130-nm albumin-bound paclitaxel 5sintilimab 4camrelizumab 4Leucovorin 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Surveys and Questionnaires 3Endoscopy 3Bevacizumab 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Esophageal Neoplasms × Radiotherapy, Adjuvant × Clear all
NCT06272214 2024-07-16

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

Zhejiang Cancer Hospital

Phase 2 Recruiting
146 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡